Anvisa – 25th anniversary of the Generics Policy
The generic drugs policy, established in 1999, represented an important step forward for the country’s public health.
Reports assess risk and benefit of drug list
ANVISA has announced the availability of the list of medicines that must submit Periodic Benefit-Risk Assessment Reports.
Anvisa approves new Covid-19 vaccine
The covid-19 (recombinant) immunizing zika vaccine with s-protein and saponin-based adjuvant has been approved.
Anvisa publishes new edition of the Biosurveillance Manual
The document provides guidelines on monitoring adverse events in transplants, grafts and assisted human reproduction.
Brazil to be present at 15 global food fairs in 2023
MAPA aims to boost national agribusiness, taking advantage of opportunities to promote Brazilian products on the market.
Anvisa approves new treatment for advanced cancer in Brazil
Anvisa has approved a gene therapy drug to treat hematologic cancer (gene therapy using patients’ genetically modified T cells).
Anvisa allows use of packaging and label reserves
The impacts of the pandemic prompted the decision due to logistical challenges and variations in purchasing power in the food sector.
Updating the Brazilian Pharmacopoeia
As of January 2, 2024, companies have 180 days from the date the standard comes into force to adapt their procedures.
Joint operation to combat illegal imports
Anvisa and Receita Federal inspect luggage to identify illegal imports of products subject to health surveillance.
Cofepris facilitates access to innovative medicines
Cofepris has taken important steps to facilitate the population’s access to high-quality biotechnologicals and biosimilars.